Phase I results of inhaled 5-azacytidine for the treatment of advanced non-small cell lung cancer Sep. 9, 2019
PRC2 inhibitors patented by Shanghai Institute of Materia Medica, Suzhou Suplead Life Sciences Sep. 9, 2019
Phase II results support further study of AAV2-REP1 gene therapy in patients with choroideremia Sep. 9, 2019
RSS